Share on Facebook
Share on Twitter
Share on LinkedIn

Medical device maker Medtronic has agreed to pay investors $43 million in a proposed class-action legal settlement that would resolve one of the last remaining lawsuits dogging the company’s bone-growth product Infuse.

The institutional investors who sued Medtronic alleged that the company secretly paid spine surgeons to conceal Infuse adverse events and side effects and to overstate the disadvantages of alternative treatments.

Infuse contains a synthesized human protein that causes bone to grow, avoiding the need for other bone-graft materials for spine-fusion surgery. It can also lead to unwanted bone growth and swelling.

Read More